How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both?
Author:
- 6 January 2009
- journal article
- review article
- Published by Wiley in Annals of Neurology
- Vol. 64 (S2) , S56-S64
Abstract
The motor complications associated with levodopa therapy, namely, fluctuations in motor response and dyskinesias, occur in the majority of Parkinson's disease patients. These complications can impair a patient's quality of life and even cause pronounced disability. “Off” states that result in freezing of gait and falling are disabling for many patients. Dyskinesias most commonly occur at peak dose and typically alternate with the wearing‐off state. Once these problems appear, they usually persist, and the physician needs to make continual adjustments in medications to minimize these problems. Medical treatments should be attempted before treatments such as deep brain stimulation are considered because of the potential adverse effects that are associated with surgery. The timing of surgery, however, is also important because younger patients and less advanced patients tend to have a better outcome. There is thus a need for experienced and knowledgeable physicians and surgeons who are able to handle these motor complications. This review discusses available medications and surgical approaches, and their outcomes. Ann Neurol 2008;64 (suppl):S56–S64Keywords
This publication has 86 references indexed in Scilit:
- Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcomeMovement Disorders, 2007
- Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population?Neurology, 2007
- Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopaMovement Disorders, 2006
- Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET studyMovement Disorders, 2006
- Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow upJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's diseaseMovement Disorders, 2005
- Tolcapone and fulminant hepatitisThe Lancet, 1998
- Early Treatment of Parkinson??s Disease with Cabergoline Delays the Onset of Motor ComplicationsDrugs, 1998
- Motor fluctuations during continuous levodopa infusions in patients with Parkinson's diseaseMovement Disorders, 1997
- Suppression of dyskinesias in advanced Parkinson's disease: Moderate daily clozapine doses provide long‐term dyskinesia reductionMovement Disorders, 1994